524494 Stock Overview
A pharmaceutical company, manufactures and markets formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments in India, Europe, Africa, the Americas, Asia, CIS, and Australasia. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 4/6 |
| Past Performance | 4/6 |
| Financial Health | 5/6 |
| Dividends | 4/6 |
My Notes
Capture your thoughts, links and company narrative
Ipca Laboratories Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹1,593.35 |
| 52 Week High | ₹1,708.70 |
| 52 Week Low | ₹1,057.20 |
| Beta | 0.26 |
| 1 Month Change | 1.82% |
| 3 Month Change | 7.84% |
| 1 Year Change | 45.26% |
| 3 Year Change | 46.44% |
| 5 Year Change | 179.27% |
| Change since IPO | 1,955.94% |
Recent News & Updates
Recent updates
Shareholder Returns
| 524494 | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | -0.006% | -0.7% | -1.8% |
| 1Y | 45.3% | 37.7% | 17.5% |
Return vs Industry: 524494 exceeded the Indian Pharmaceuticals industry which returned 38.1% over the past year.
Return vs Market: 524494 exceeded the Indian Market which returned 17.9% over the past year.
Price Volatility
| 524494 volatility | |
|---|---|
| 524494 Average Weekly Movement | 4.0% |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in IN Market | 9.1% |
| 10% least volatile stocks in IN Market | 4.1% |
Stable Share Price: 524494 has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: 524494's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1949 | 17,335 | Pranay Godha | www.ipca.com |
Ipca Laboratories Limited, a pharmaceutical company, manufactures and markets formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments in India, Europe, Africa, the Americas, Asia, CIS, and Australasia. It offers APIs in therapeutic areas of anti-hypertensive, anti-malarial, diuretic, DMARD, and anthelmintic. The company also provides generic and branded formulations in the therapeutic segments, including allergy, anti-neoplastic/cancer drugs, anti-arthritic, anti-epileptic, anti-hypertensive, cardiology, diabetes, dermatology, diabetology, emollients/protectives, fever, gastroenterology, hematology, helminthics, hepatoprotectives, immunosuppressant, infectious diseases, malaria, neurology, neuropathic pain, and NSAIDs, as well as nutraceuticals, ophthalmology, oral anti diabetes drug, orthopedics, probiotics, psychiatry, respiratory, rheumatology, and urology.
Ipca Laboratories Limited Fundamentals Summary
| 524494 fundamental statistics | |
|---|---|
| Market cap | ₹404.51b |
| Earnings (TTM) | ₹6.61b |
| Revenue (TTM) | ₹85.34b |
61.2x
P/E Ratio4.7x
P/S RatioIs 524494 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 524494 income statement (TTM) | |
|---|---|
| Revenue | ₹85.34b |
| Cost of Revenue | ₹30.57b |
| Gross Profit | ₹54.78b |
| Other Expenses | ₹48.16b |
| Earnings | ₹6.61b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 26.06 |
| Gross Margin | 64.18% |
| Net Profit Margin | 7.75% |
| Debt/Equity Ratio | 14.2% |
How did 524494 perform over the long term?
See historical performance and comparisonDividends
0.3%
Current Dividend Yield15%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/26 08:27 |
| End of Day Share Price | 2024/12/26 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Ipca Laboratories Limited is covered by 46 analysts. 19 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Aditya Khemka | Ambit Capital |
| null null | Anand Rathi Shares and Stock Brokers Limited |
| Sanjeev Chiniwar | Anand Rathi Shares and Stock Brokers Limited |